Continuing Medical Education Questions: July 2019.

Continuing Medical Education Questions: July 2019. Am J Gastroenterol. 2019 Jul;114(7):1026 Authors: Veerappan GR Abstract Article Title: The Gut Microbiome in Other Chronic Immune Disease: Lessons for Inflammatory Bowel Disease. PMID: 31268915 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31268915?dopt=Abstract

Read More

The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases.

The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases. Am J Gastroenterol. 2019 Jun 20;: Authors: Knox NC, Forbes JD, Peterson CL, Van Domselaar G, Bernstein CN Abstract There is a growing appreciation for the role of the gut microbiome in human health and disease. Aided by advances in sequencing technologies and analytical methods, recent research has shown the healthy gut microbiome to possess considerable diversity and functional capacity. Dysbiosis of the gut microbiota is believed to be involved in the pathogenesis of not only…

Read More

High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease.

High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. Am J Gastroenterol. 2019 Jun 13;: Authors: Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist CA, Posfay-Barbe KM, Swiss Inflammatory Bowel Disease Cohort Study Group Abstract INTRODUCTION: Patients with inflammatory bowel disease (IBD) are predisposed to pneumococcal infections due to their underlying disease and iatrogenic immunosuppression. Vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) is recommended, but with poor take-up and few data available. We performed an open-label, phase…

Read More

Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers.

Related Articles Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers. Am J Gastroenterol. 2019 May;114(5):771-776 Authors: Mañosa M, Chaparro M, Juan A, Aràjol C, Alfaro I, Mínguez M, Velayos B, Benítez JM, Mesonero F, Sicilia B, Zabana Y, Villoria A, Gisbert JP, Domènech E, ENEIDA registry by GETECCU Abstract OBJECTIVES: Immunosuppressant therapies (IMTs; thiopurines, anti-tumor necrosis factor agents) may influence the immunologic control of cancer and might facilitate the spread and recurrence of cancer. This study assesses…

Read More

Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn’s Disease.

Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn’s Disease. Am J Gastroenterol. 2019 May;114(5):777-785 Authors: Wu J, Lubman DM, Kugathasan S, Denson LA, Hyams JS, Dubinsky MC, Griffiths AM, Baldassano RN, Noe JD, Rabizadeh S, Gulati AS, Rosh JR, Crandall WV, Higgins PDR, Stidham RW Abstract OBJECTIVES: Avoiding fibrostenotic complications is of paramount concern in the management of Crohn’s disease (CD). We sought to investigate the association of candidate biomarkers of fibrosis collected at diagnosis with the future development of fibrostenotic CD.…

Read More

Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2019 Apr 29;: Authors: Singh S, Proudfoot J, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ PMID: 31033520 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31033520?dopt=Abstract

Read More

Histologic Remission in Ulcerative Colitis: Are We There Yet?

Histologic Remission in Ulcerative Colitis: Are We There Yet? Am J Gastroenterol. 2019 Apr 22;: Authors: Long MD, Rubin DT Abstract As the field of inflammatory bowel disease moves toward treating to a “target” that includes mucosal healing, better outcome definitions are needed. One important question is whether the definition of mucosal healing should include “histologic” remission. In this systematic review and meta-analysis, the authors describe histologic healing rates of medical therapies for ulcerative colitis in randomized controlled trials. Although observational data demonstrate that histologic remission has consistently been associated…

Read More

Inflammatory Bowel Disease: A Practical Path to Transitioning From Pediatric to Adult Care.

Inflammatory Bowel Disease: A Practical Path to Transitioning From Pediatric to Adult Care. Am J Gastroenterol. 2019 Apr 12;: Authors: Menon T, Afzali A Abstract The growing need for transitional care is quickly becoming apparent in the medical community because children with chronic illnesses are surviving into adulthood. Transitional care is the coordinated movement of young adults with chronic conditions from the pediatric to adult health care setting. This transition period is associated with poorer health outcomes due to differences in pediatric and adult health care models, reluctance to change…

Read More

Manipulation of the Gut-Liver Axis Using Microbiome Restoration Therapy in Primary Sclerosing Cholangitis.

Manipulation of the Gut-Liver Axis Using Microbiome Restoration Therapy in Primary Sclerosing Cholangitis. Am J Gastroenterol. 2019 Mar 12;: Authors: Bajaj JS, Hays RA Abstract Alteration of the normal gut-liver axis is important in primary sclerosing cholangitis (PSC). Lack of effective medical therapy for PSC makes microbiome restoration an alluring therapeutic target. Allegretti et al. performed an open-label safety trial of fecal microbiota transplant (FMT) in noncirrhotic PSC patients with inflammatory bowel disease in remission on minimal therapy. FMT was safe in this population, and after FMT, there was a…

Read More
<< Go Back